{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T03:48:02Z","timestamp":1762746482405},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 \u03bcg\/mL of drug. Samples were tested using 3 different prothrombin time\/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non\u2013phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 \u03bcg\/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 \u03bcg\/mL.<\/jats:p>","DOI":"10.1309\/ajcpdpl4g7ceryju","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T10:33:56Z","timestamp":1321526036000},"page":"848-854","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Telavancin (Vibativ) on Routine Coagulation Test Results"],"prefix":"10.1093","volume":"136","author":[{"given":"Robert","family":"Gosselin","sequence":"first","affiliation":[{"name":"1Medical Pathology and Laboratory Medicine, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Dager","sequence":"additional","affiliation":[{"name":"2Pharmacy, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Roberts","sequence":"additional","affiliation":[{"name":"2Pharmacy, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Freeman","sequence":"additional","affiliation":[{"name":"1Medical Pathology and Laboratory Medicine, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Gandy","sequence":"additional","affiliation":[{"name":"1Medical Pathology and Laboratory Medicine, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Gregg","sequence":"additional","affiliation":[{"name":"1Medical Pathology and Laboratory Medicine, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Dwyre","sequence":"additional","affiliation":[{"name":"1Medical Pathology and Laboratory Medicine, University of California, Davis Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"2023012003000237800_b1-1360848","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0149-2918(11)00020-8","article-title":"Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram positive bacteria in adults","volume":"32","author":"Chang","year":"2010","journal-title":"Clin Ther"},{"key":"2023012003000237800_b2-1360848","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012003000237800_b3-1360848","article-title":"Vibativ [package insert]","year":"2009"},{"key":"2023012003000237800_b4-1360848","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.01750-09","article-title":"Mass balance and pharmacokinetics of [14C] telavancin following intravenous administration to healthy male volunteers","volume":"54","author":"Shaw","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012003000237800_b5-1360848","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","article-title":"Multiple dose pharmacokinetics of intravenous telavancin in healthy male and female subjects","volume":"62","author":"Wong","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2023012003000237800_b6-1360848","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012003000237800_b7-1360848","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023012003000237800_b8-1360848","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0038-1642433","article-title":"Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids","volume":"71","author":"Bader","year":"1994","journal-title":"Thromb Haemost"},{"key":"2023012003000237800_b9-1360848","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1538-7836.2004.00897.x","article-title":"Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI)","volume":"2","author":"Smith","year":"2004","journal-title":"J Thromb Haemost"},{"key":"2023012003000237800_b10-1360848","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2006.01848.x","article-title":"Phospholipid composition controls thromboplastin sensitivity to individual clotting factors","volume":"4","author":"Smith","year":"2006","journal-title":"J Thromb Haemost"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/136\/6\/848\/48790905\/ajcp_136_6_848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/136\/6\/848\/48790905\/ajcp_136_6_848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T03:03:27Z","timestamp":1674183807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/136\/6\/848\/1760511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpdpl4g7ceryju","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,12,1]]},"published":{"date-parts":[[2011,12,1]]}}}